Subscribe to Search results

An editorial in The British Medical Journal entitled "Blood Donors and the Transfusion Service" argued that the blood services were ill-equipped to do the job as a modern transfusion service, suggesting that the "shortage" of blood and therefore plasma, allowing entry to the UK of the products of pharmaceutical companies, was not a real shortage, but a consequence of poor administration, organisation and underfunding.

Published on:

Andrew Mitchell wrote a letter to Malcolm Widdup noting the SHHD's proposal that the new blood products unit "should operate on the continuous flow principle and should be designed to a workload of 1,500 litres of plasma per week; but it will be capable of adaptation, without substantial structural alterations, to operate at levels up to 3,000 litres per week should this become necessary".

Published on:

The discussion in the Expert Group on the Treatment of Haemophilia - in particular its belief that "with the extension of home treatment joint surgery etc the current target may represent no more than _ to _ of the amount of Factor VIII which may be required in 5 years time or less" - was reported to the Central Committee of the National Blood Transfusion Service.

Published on:

The special allocations appear to have become subsumed as a part of the standard regional allocations, revised "in the usual way" to take account of cost increases.

Published on:

The Expert Report to the Infected Blood Inquiry: Public Health and Administration was produced, providing some evidence of the constrained financial position of the UK during the 1970s.

Published on:

A booklet entitled "Notes on Transfusion" was issued by the DHSS, SHHD and the Welsh Office.

Published on:

Dr Owen authorised the allocation of special finance to assist the National Health Service in becoming self-sufficient as soon as practicable.

Published on:

Dr Owen pointed in Parliament to the £500,000 of special financing which was to increase the existing production of Factor 8.

Published on:

Dr Mayne described that haemophilia patients in Northern Ireland who were treated with concentrate received limited quantities of concentrate from Elstree and Oxford.

Published on:

The UK was self-sufficient in meeting Factor 9 needs, and remained so until products sourced from British donor plasma ceased being used because of the threat of vCJD.

Published on:

Dr Biggs maintained that concentrates were the optimum treatment; that commercial product was available but, despite that, UK domestic production should increase; and that home treatment was desirable as a goal.

Published on:

Dr Maycock recognised a need for blood transfusion services to be "self-supporting".

Published on:

The goal of 275,000 donations for Factor 8 production had not been met a year after it had been given.

Published on:

Dr Maycock described that the Department of Health had been advised that the NBTS should reach the position of being able to supply the amount of concentrate from 275,000 donations by 1975, but this was clearly not possible.

Published on:

The DHSS and Dr Maycock understood that it was the supply of plasma for fractionation which needed to increase if the shortfall in meeting anticipated demand was to be met from within the NHS.

Published on:

The SHHD considered that the present dependence on commercial supplies of anti-haemophilic globulin concentrate and PPF posed a threat to the unpaid voluntary donor system.

Published on:

It was suggested that plasmapheresis should be practised more widely and rather more intensively than was currently being done.

Published on:

A number of regional transfusion centres had experienced an increase in demand for cryoprecipitate.

Published on:

The unpaid volunteers began donating by plasmapheresis at the North London Blood Transfusion Centre, Edgware.

Published on:

The number of regular attendees at the North London Blood Transfusion Centre, Edgware, exceeded 2,500 and over 80% of the donors attended for donation once a fortnight.

Published on: